Floriane Michel1,2, Fabiana Cancrini3,4, Henri Bensadoun5, Olivier Cussenot3,6, Cyrille Guillot-Tantay7, Morgan Rouprêt3,8, Gilles Karsenty9, Véronique Phé3,6. 1. Department of Urology and Kidney Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Aix-Marseille University, 147 boulevard Baille, 13005, Marseille, France. floriane.michel@ap-hm.fr. 2. GRC5 Predictive Onco-urology AP-HP, Sorbonne University, Paris, France. floriane.michel@ap-hm.fr. 3. GRC5 Predictive Onco-urology AP-HP, Sorbonne University, Paris, France. 4. Department of Medical and Surgical Sciences and Translational Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy. 5. Department of Urology, CHU de Bordeaux, Bordeaux, France. 6. Department of Urology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France. 7. Department of Urology, Foch Hospital, Suresnes, France. 8. Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Paris, France. 9. Department of Urology and Kidney Transplantation, Assistance Publique-Hôpitaux de Marseille, La Conception Hospital, Aix-Marseille University, 147 boulevard Baille, 13005, Marseille, France.
Abstract
PURPOSE: The purpose of this study was to evaluate the incidence of bladder cancer (BCa) in patients with the main neurological diseases that induce neurogenic lower urinary tract dysfunction, namely, multiple sclerosis (MS), spinal cord injury (SCI) and spina bifida (SB). METHODS: We conducted a retrospective analysis of nationwide data from the French Hospital Discharge Database (PMSI) from January 2010 to December 2018. The incidence of BCa was calculated in patients with MS, SCI and SB. Incidence, sex, age, radical cystectomy after BCa diagnosis and in-hospital deaths were compared between the three groups. The Chi2 and Kruskal-Wallis tests were used for qualitative and quantitative data comparisons, respectively. RESULTS: Overall, 2015 neuro-urological patients (mean (± SD) age: 65.4 ± 12.3 years) were hospitalized in France between 2010 and 2018 with a new diagnosis of BCa. In neuro-urological patients, BCa was more frequent in men than in women (sex ratio: 3.08). The incidence of BCa in neuro-urological patients was 174.9/100,000 persons/year. The incidence of BCa was 791.1/100,000 persons/year in SCI compared to 56.6 in MS and 113.8 in SB (p < 0.0001). After the initial diagnosis of BCa, 551 (27.3%) patients underwent a radical cystectomy and 613 (30.4%) died in hospital after BCa diagnosis. CONCLUSIONS: The incidence of BCa in France between 2010 and 2018 was 174.9/100 000 persons/year, and was particularly high in patients with SCI.
PURPOSE: The purpose of this study was to evaluate the incidence of bladder cancer (BCa) in patients with the main neurological diseases that induce neurogenic lower urinary tract dysfunction, namely, multiple sclerosis (MS), spinal cord injury (SCI) and spina bifida (SB). METHODS: We conducted a retrospective analysis of nationwide data from the French Hospital Discharge Database (PMSI) from January 2010 to December 2018. The incidence of BCa was calculated in patients with MS, SCI and SB. Incidence, sex, age, radical cystectomy after BCa diagnosis and in-hospital deaths were compared between the three groups. The Chi2 and Kruskal-Wallis tests were used for qualitative and quantitative data comparisons, respectively. RESULTS: Overall, 2015 neuro-urological patients (mean (± SD) age: 65.4 ± 12.3 years) were hospitalized in France between 2010 and 2018 with a new diagnosis of BCa. In neuro-urological patients, BCa was more frequent in men than in women (sex ratio: 3.08). The incidence of BCa in neuro-urological patients was 174.9/100,000 persons/year. The incidence of BCa was 791.1/100,000 persons/year in SCI compared to 56.6 in MS and 113.8 in SB (p < 0.0001). After the initial diagnosis of BCa, 551 (27.3%) patients underwent a radical cystectomy and 613 (30.4%) died in hospital after BCa diagnosis. CONCLUSIONS: The incidence of BCa in France between 2010 and 2018 was 174.9/100 000 persons/year, and was particularly high in patients with SCI.
Authors: Suzanne L Groah; David A Weitzenkamp; Daniel P Lammertse; Gale G Whiteneck; Dennis C Lezotte; Richard F Hamman Journal: Arch Phys Med Rehabil Date: 2002-03 Impact factor: 3.966
Authors: Laura E Mitchell; N Scott Adzick; Jeanne Melchionne; Patrick S Pasquariello; Leslie N Sutton; Alexander S Whitehead Journal: Lancet Date: 2004 Nov 20-26 Impact factor: 79.321
Authors: Ralf Böthig; Birgitt Kowald; Kai Fiebag; Oliver Balzer; Christian Tiburtius; Roland Thietje; Thura Kadhum; Klaus Golka Journal: Spinal Cord Date: 2021-06-17 Impact factor: 2.772